ReviR Therapeutics Named to 2026 Future Healthcare Top 100: Innovative Pharmaceuticals & Biologics List

The Future Healthcare 100 list consistently focuses on China's healthcare innovation forces. This year’s selection emphasizes "the presentation, trading, and empowerment of innovative assets in China's healthcare industry," covering three major fields: innovative medical devices and smart manufacturing, innovative pharmaceuticals and biologics, and innovative health services and industrial chain services. The list has refined its criteria to further concentrate on these areas.High Potential, High MomentumThe innovative target. The list is based on the threshold of "having financing activities since 2023," selecting active innovation entities,Precisely Focus on High-Quality Enterprises in the Growth Acceleration Phase。

This selection is a recognition of ReviR Therapeutics' innovation capabilities, platform value, and development potential. In the future, ReviR Therapeutics will continue to leverage its self-developed AI platform, VoyageR, to advance the research and development of RNA-modulating small molecule drugs and core pipelines, bringing new therapeutic possibilities for significant unmet clinical needs such as neurological disorders.